Market Size of Enzyme Replacement Therapy Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.70 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Enzyme Replacement Therapy Market Analysis
The enzyme replacement therapy market is expected to register a CAGR of 7.7% during the forecast period. The increasing burden of rare diseases and the initiatives taken by the government and others for rare diseases is expected to be a key contributor in the enzyme replacement therapy market growth. In 2018, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) granted the marketing authorization for Lamzede used for treating Alpha-mannosidosis in the European Union. According to the EURORDIS, currently, there are over 6000 rare diseases in existence, and around 30 million of the population in Europe has been affected by it. Furthermore, at least 80% of these rare disorders are chronic and life-threatening. Hence, the treatment of rare diseases is of utmost importance, thereby, boosting the enzyme replacement therapy market growth.
Enzyme Replacement Therapy Industry Segmentation
Enzyme replacement therapy is a type of medical treatment, in which an enzyme is replaced that is deficient or absent in the body. Most commonly, this procedure is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme. The enzyme replacement therapy market is segmented by enzyme type, application, and geography.
| By Enzyme Type | |
| Agalsidase Alfa | |
| Agalsidase Beta | |
| Galsulfase | |
| Other Enzyme Types |
| By Application | |
| Gaucher disease | |
| Pompe disease | |
| Fabry Disease | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Enzyme Replacement Therapy Market Size Summary
The enzyme replacement therapy market is poised for significant growth, driven by the increasing prevalence of rare diseases and supportive government initiatives. The market is expected to expand steadily over the forecast period, with key developments such as the European Medicines Agency's approval of Lamzede for treating Alpha-mannosidosis highlighting the ongoing efforts to address rare disorders. The chronic and life-threatening nature of over 6000 rare diseases, affecting millions in Europe alone, underscores the critical need for effective treatments, thereby fueling market expansion. The treatment of Fabry disease, a lysosomal storage disorder, exemplifies this trend, with Algasidase Alfa being a notable therapeutic option. The high prevalence of Fabry disease, particularly among dialysis patients, further emphasizes the demand for enzyme replacement therapies.
North America is anticipated to maintain a dominant position in the global enzyme replacement therapy market, supported by substantial government and organizational efforts to combat rare diseases. Initiatives by the National Institutes of Health and the National Center for Advancing Translational Sciences reflect a robust commitment to rare disease research and treatment, contributing to the region's market share. The presence of major industry players such as Genzyme Corporation, Pfizer Inc., and Takeda Pharmaceutical Company Limited, along with strategic initiatives to enhance market presence, further bolster the market's growth prospects. These companies are actively involved in advancing therapies for lysosomal storage disorders, as evidenced by Takeda's recent presentations at industry symposiums, reinforcing their leadership in the enzyme replacement therapy sector.
Enzyme Replacement Therapy Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rising Prevalence of Rare Diseases
-
1.2.2 Increasing Government Initiatives for Rare Diseases
-
-
1.3 Market Restraints
-
1.3.1 High Cost of the Treatment
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Enzyme Type
-
2.1.1 Agalsidase Alfa
-
2.1.2 Agalsidase Beta
-
2.1.3 Galsulfase
-
2.1.4 Other Enzyme Types
-
-
2.2 By Application
-
2.2.1 Gaucher disease
-
2.2.2 Pompe disease
-
2.2.3 Fabry Disease
-
2.2.4 Other Applications
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East & Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East & Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Enzyme Replacement Therapy Market Size FAQs
What is the current Enzyme Replacement Therapy Market size?
The Enzyme Replacement Therapy Market is projected to register a CAGR of 7.70% during the forecast period (2024-2029)
Who are the key players in Enzyme Replacement Therapy Market?
Genzyme Corporation, Pfizer Inc., Leadiant Biosciences Inc., Biomarin Pharmaceuticals Inc. and Takeda pharmaceutical Company Ltd. are the major companies operating in the Enzyme Replacement Therapy Market.
